Anglo-Swedish drugmaker AstraZeneca and Germany's Boehringer Ingelheim said earlier this month they would cap out-of-pocket costs for their inhaled respiratory products at $35 per month in the U.S.
Some results have been hidden because they may be inaccessible to you